Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB

← catalyst calendar

NCT05708677 · readout ≤ 3,481 d

Sponsored by Abeona Therapeutics, Inc (industry) · ABEO — their whole pipeline →.

Phase
Status
Enrolling by invitation
Study type
Observational
Enrollment
22estimated
Sites
2
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2021-02-09actualWhen the study began enrolling
Primary completionFeb 2036estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completionAug 2036estimatedThe whole study's end, after follow-up
First posted2023-02-01actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-07-17actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • RDEB

Intervention

  • Biological: EB-101 — also filed as pz-cel

Primary outcomes

what the primary-completion date above is the date OF
Wound Closure
measured 5 years
Pain Severity Scale (Wong-Baker FACES)
measured 5 years
Itch Severity Scale
measured 5 years
Zarit Burden Interview Scale
measured 5 years
Quality of Life in Epidermolysis Bullosa
measured 5 years
Caregiver Global Impression of Change for Pain Scale
measured 5 years
Wound Infection and Adverse Events
measured 5 years
The number of treatment-emergent adverse events.
measured 5 years
Serious Adverse Events
measured 5 years
Incidence of squamous cell carcinoma.
measured 5 years
Replication-competent retrovirus (RCR) status
measured 5 years

Permalink · ABEO's whole pipeline · Catalyst calendar · Every registered study · What changed